QNRX: Quoin Pharmaceuticals Ltd.
About
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.
Current Value
$0.641 Year Return
Current Value
$0.641 Year Return
Key Details
Market Cap
$3.20M
P/E Ratio
-0.16
1Y Stock Return
-85.07%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
0.6
Strategies that include QNRX
Stock's related to QNRX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KRRO | 37.92% | $436.84M | +20.68% | 0.00% |
| SEMR | 25.99% | $2.07B | +42.81% | 0.00% |
| LEU | 25.67% | $1.12B | +33.82% | 0.00% |
| VYGR | 25.21% | $287.88M | -21.46% | 0.00% |
| XNCR | 24.60% | $1.65B | +27.73% | 0.00% |
| PCG | 24.49% | $44.89B | +18.38% | 0.19% |
| TVTX | 23.29% | $1.51B | +207.79% | 0.00% |
| ZYME | 23.25% | $1.03B | +79.68% | 0.00% |
| ALB | 22.98% | $12.51B | -15.60% | 1.50% |
| DMRC | 22.48% | $694.39M | -2.06% | 0.00% |
| SEAT | 22.40% | $478.73M | -52.29% | 0.00% |
| AUTL | 22.30% | $785.05M | -27.16% | 0.00% |
| BBIO | 22.06% | $4.26B | -20.38% | 0.00% |
| FCPT | 21.82% | $2.81B | +27.91% | 4.79% |
| BCE | 21.69% | $24.91B | -30.63% | 10.69% |
| ALTM | 21.36% | $5.58B | -23.79% | 0.00% |
| AWK | 21.25% | $26.93B | +5.63% | 2.17% |
| OKLO | 21.22% | $2.66B | +111.04% | 0.00% |
| MDT | 21.11% | $109.01B | +8.12% | 3.27% |
| SMLR | 21.09% | $336.72M | +25.48% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FTRE | <0.01% | $1.68B | -42.77% | 0.00% |
| AUB | -0.01% | $3.75B | +32.11% | 3.13% |
| LDOS | -0.01% | $21.12B | +49.80% | 0.96% |
| OCX | -0.02% | $42.93M | -36.09% | 0.00% |
| CSTL | -0.03% | $808.57M | +48.97% | 0.00% |
| IRM | 0.03% | $34.19B | +84.79% | 2.31% |
| TBI | -0.04% | $199.52M | -50.80% | 0.00% |
| LZ | -0.04% | $1.30B | -33.57% | 0.00% |
| MX | 0.04% | $135.79M | -45.52% | 0.00% |
| BGC | 0.05% | $4.97B | +59.88% | 0.48% |
| SPR | -0.06% | $3.72B | +23.27% | 0.00% |
| BOOT | 0.06% | $4.06B | +85.40% | 0.00% |
| TD | -0.06% | $97.59B | -9.20% | 5.39% |
| IESC | -0.07% | $5.70B | +320.30% | 0.00% |
| BKU | 0.07% | $3.10B | +58.18% | 2.75% |
| WNC | 0.07% | $804.33M | -13.95% | 1.72% |
| XPEL | 0.08% | $1.18B | -7.73% | 0.00% |
| RDN | -0.08% | $5.04B | +32.94% | 2.84% |
| CLH | -0.09% | $13.30B | +50.38% | 0.00% |
| KOP | 0.11% | $757.45M | -12.85% | 0.74% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AVAV | -21.79% | $5.50B | +51.29% | 0.00% |
| PENG | -20.05% | $911.79M | +4.97% | 0.00% |
| DAVE | -20.01% | $1.04B | +1,258.83% | 0.00% |
| BSM | -18.77% | $3.17B | -13.01% | 10.65% |
| SVC | -18.58% | $431.62M | -63.31% | 23.74% |
| HIHO | -15.41% | $8.63M | 0.00% | 6.12% |
| NNE | -15.16% | $833.66M | +531.50% | 0.00% |
| MTRX | -14.57% | $358.21M | +30.13% | 0.00% |
| NTZ | -13.91% | $47.64M | -30.94% | 0.00% |
| OFG | -13.36% | $1.99B | +30.61% | 2.23% |
| ORLY | -12.52% | $69.31B | +22.06% | 0.00% |
| LRN | -11.77% | $4.43B | +74.97% | 0.00% |
| FMS | -11.40% | $12.97B | +12.47% | 2.97% |
| FTI | -11.33% | $12.24B | +36.61% | 0.87% |
| FCN | -11.17% | $7.10B | -10.74% | 0.00% |
| LITB | -10.59% | $35.48M | -75.45% | 0.00% |
| DXPE | -10.38% | $1.07B | +119.39% | 0.00% |
| KR | -10.23% | $42.03B | +35.08% | 2.11% |
| MGPI | -10.14% | $1.02B | -48.95% | 1.04% |
| IBKR | -10.05% | $20.20B | +131.83% | 0.37% |
ETF's related to QNRX
News
Yahoo
By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT U.S. and International Sites participating in QRX003 NS study, Expanding to study QRX003 for additional indications and in younger patient populations Quoin Pharmaceuticals (NASDAQ:QNRX) provided a business update last week. The company implemented a number of measures during the quarter to move lead asset QRX003 forward. For instance,
Yahoo
Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton Syndrome Clinical Trials Significant Insider Share Purchases by the Entire Management Team ASHBURN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and anno
Yahoo
Clinical Assessment Is Being Performed on a Pediatric Patient at Children’s Health Ireland in Dublin First Evaluation of QRX003 in a Pediatric Patient Second Clinical Site to Open in Spain with Potentially Three Additional Pediatric Netherton Patients ASHBURN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company focused on novel treatments for rare and orphan diseases, today announced that it has initiated the testing
Yahoo
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2024 financial results before the market opens on Thursday, November 7, 2024. The announcement will provide an operational update regarding the Company’s achievements during the quarter and will detail financial highlights. Abo
Yahoo
Two Additional Clinical Sites to be Opened in the United Kingdom Both Sites are Recognized Centers of Excellence for Netherton Syndrome in the UK. Principal Investigator has Been Appointed and a Clinical Research Organization Has Been Engaged Additional Sites in other Western European Countries are being Finalized ASHBURN, Va., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare
Yahoo
Purchases Signal Leadership Confidence and Commitment to CompanyASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today announced that its Chief Executive Officer, Michael Myers, and Chief Operating Officer, Denise Carter, have recently made significant purchases of the company’s American Depositary Shares (ADSs), signali
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.